Pfizer press release, May 2019 – The U.S. Food and Drug Administration approved VYNDAQEL (tafamidis) and VYNDAMAX (tafamidis) to treat transthyretin amyloid cardiomyopathy, the first approved drug for the disease.
Pfizer press release, May 2019 – The U.S. Food and Drug Administration approved VYNDAQEL (tafamidis) and VYNDAMAX (tafamidis) to treat transthyretin amyloid cardiomyopathy, the first approved drug for the disease.